COVAXIN® (BBV152) booster dose study shows Promising Results
The phase 2, double-blind, randomised controlled COVAXIN® trial demonstrated long-term safety with no serious adverse events. 6 months after receipt of the second COVAXIN® dose: Durable neutralising, T and B cell responses detected, which suggests good immune memory…









